erdafitinib   Click here for help

GtoPdb Ligand ID: 9039

Synonyms: Balversa® | compound 4 [WO2011135376] [3] | JNJ 42756493 | JNJ-42756493 | JNJ42756493
Approved drug PDB Ligand
erdafitinib is an approved drug (FDA (2019))
Compound class: Synthetic organic
Comment: Erdafitinib is a pan-fibroblast growth factor receptor (FGFRs 1-4) tyrosine kinase inhibitor [1-3]. It is the first targeted drug to be approved for advanced bladder cancer.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 77.33
Molecular weight 446.24
XLogP 3.59
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(OC)cc(c1)N(c1ccc2c(c1)nc(cn2)c1cnn(c1)C)CCNC(C)C
Isomeric SMILES COc1cc(OC)cc(c1)N(c1ccc2c(c1)nc(cn2)c1cnn(c1)C)CCNC(C)C
InChI InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3
InChI Key OLAHOMJCDNXHFI-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Erdafitinib was granted FDA approval in April 2019, as a treatment for patients with locally advanced/metastatic bladder cancer (urothelial carcinoma) that carries FGFR2/3 genetic alterations, and that has progressed following treatment with platinum-based chemotherapy. In clinical trial, responses to erdafitinib were observed in patients who had previously not responded to anti-PD-L1/PD-1 checkpoint inhibitor immunotherapy [4].